Deerfield Management Company, L.P. (Series C) Viking Therapeutics, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$4.76 Billion
Q2 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$17.4 - $94.5 $14.2 Million - $77.1 Million	-815,499 Reduced 63.76%	463,501 $38 Million
Q3 2023 Nov 14, 2023	BUY	$10.92 - $16.0 $1.68 Million - $2.46 Million	154,000 Added 13.69%	1,279,000 $14.2 Million
Q1 2023 May 15, 2023	BUY	$8.08 - $17.33 $9.09 Million - $19.5 Million	1,125,000 New	1,125,000 $18.7 Million
Q4 2020 Feb 16, 2021	SELL	$5.3 - $6.71 $1.85 Million - $2.34 Million	-348,441 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$5.73 - $8.11 $2 Million - $2.83 Million	348,441 New	348,441 $2.03 Million
Q4 2018 Feb 14, 2019	SELL	$7.16 - $16.21 $3.29 Million - $7.46 Million	-460,000 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$9.7 - $19.65 $4.46 Million - $9.04 Million	460,000 New	460,000 $8.01 Million

Others Institutions Holding VKTX

# of Institutions

442

Shares Held

63.3M

Call Options Held

6.23M

Put Options Held

2.97M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.83B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account